NO20012090L - Anvendelse av thiazolidindioner alene eller sammen med andre midler for å blokkere oxytocin medierte virkninger så somuterinsammentrekninger ved prematur födsel eller laktasjon - Google Patents

Anvendelse av thiazolidindioner alene eller sammen med andre midler for å blokkere oxytocin medierte virkninger så somuterinsammentrekninger ved prematur födsel eller laktasjon

Info

Publication number
NO20012090L
NO20012090L NO20012090A NO20012090A NO20012090L NO 20012090 L NO20012090 L NO 20012090L NO 20012090 A NO20012090 A NO 20012090A NO 20012090 A NO20012090 A NO 20012090A NO 20012090 L NO20012090 L NO 20012090L
Authority
NO
Norway
Prior art keywords
alone
thiazolidinediones
lactation
agents
block
Prior art date
Application number
NO20012090A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012090D0 (no
Inventor
Iii John A Copland
Kirk L Ives
Melvyn Soloff
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO20012090D0 publication Critical patent/NO20012090D0/no
Publication of NO20012090L publication Critical patent/NO20012090L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20012090A 1998-10-29 2001-04-27 Anvendelse av thiazolidindioner alene eller sammen med andre midler for å blokkere oxytocin medierte virkninger så somuterinsammentrekninger ved prematur födsel eller laktasjon NO20012090L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10613398P 1998-10-29 1998-10-29
PCT/US1999/025433 WO2000025781A1 (en) 1998-10-29 1999-10-29 Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation

Publications (2)

Publication Number Publication Date
NO20012090D0 NO20012090D0 (no) 2001-04-27
NO20012090L true NO20012090L (no) 2001-06-27

Family

ID=22309672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012090A NO20012090L (no) 1998-10-29 2001-04-27 Anvendelse av thiazolidindioner alene eller sammen med andre midler for å blokkere oxytocin medierte virkninger så somuterinsammentrekninger ved prematur födsel eller laktasjon

Country Status (19)

Country Link
US (1) US7528133B1 (cs)
EP (1) EP1126844A1 (cs)
JP (1) JP2002528500A (cs)
KR (1) KR20010089381A (cs)
CN (1) CN1328456A (cs)
AU (1) AU1330800A (cs)
BR (1) BR9915820A (cs)
CA (1) CA2348910A1 (cs)
CZ (1) CZ20011524A3 (cs)
HK (1) HK1041213A1 (cs)
HU (1) HUP0104900A3 (cs)
ID (1) ID29352A (cs)
IL (1) IL142841A0 (cs)
MX (1) MXPA01004257A (cs)
NO (1) NO20012090L (cs)
PL (1) PL347508A1 (cs)
TR (1) TR200101882T2 (cs)
WO (1) WO2000025781A1 (cs)
ZA (1) ZA200103999B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062563A2 (en) * 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
US10555934B2 (en) * 2016-01-04 2020-02-11 ObsEva S.A. Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
SG11202002065VA (en) 2017-09-13 2020-04-29 Progenity Inc Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
EP0844997A1 (en) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
EP1126844A1 (en) 2001-08-29
CA2348910A1 (en) 2000-05-11
JP2002528500A (ja) 2002-09-03
ZA200103999B (en) 2002-08-16
ID29352A (id) 2001-08-23
MXPA01004257A (es) 2002-06-21
HUP0104900A2 (hu) 2002-04-29
PL347508A1 (en) 2002-04-08
US7528133B1 (en) 2009-05-05
CN1328456A (zh) 2001-12-26
WO2000025781A1 (en) 2000-05-11
IL142841A0 (en) 2002-03-10
AU1330800A (en) 2000-05-22
BR9915820A (pt) 2001-10-30
KR20010089381A (ko) 2001-10-06
CZ20011524A3 (cs) 2002-01-16
HUP0104900A3 (en) 2003-02-28
HK1041213A1 (zh) 2002-07-05
NO20012090D0 (no) 2001-04-27
TR200101882T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
Buchanan et al. Return of spermatogenesis after stopping cyclophosphamide therapy
ATE328612T1 (de) Therapeutische zusammensetzungen zur behandlung von schleimhypersekretion
Van der Hulst et al. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication
NO20012090L (no) Anvendelse av thiazolidindioner alene eller sammen med andre midler for å blokkere oxytocin medierte virkninger så somuterinsammentrekninger ved prematur födsel eller laktasjon
WO2004067057A3 (en) Catheter with disruptable guidewire channel
DK0799037T3 (da) Præparat til behandling af allergisk rhinitis og andre lidelser, herunder descarboetoxyloratadin
RU93052390A (ru) Способ лечения шизофрении, применение комбинации арахидоновой и докозагексановой кислот для получения лекарственного средства для лечения шизофрении
WO2006023056A3 (en) System and method for treating cardiac arrest and myocardial infarction
WO2000064456A3 (en) Substitution infusion fluid and citrate anticoagulation
WO2007047722A3 (en) Methods for treating disorders associated with hyperlipidemia in a mammal
Miwa et al. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
CN208047649U (zh) 一种适宜规模化养羊的保定装置
CN214343208U (zh) 一种骨盆骨伤紧急处理装置
WO2006014162A3 (en) Methods of using regenerative cells in the treatment of renal diseases and disorders
Prasad et al. A comparative analysis of the efficacy of topical phenytoin with conventional wound dressing in healing of diabetic foot ulcers
Riedl et al. A Prospective Randomized Placebo-Controlled Multicenter Study on the Efficacy of Intravesical Hyaluronan in Bladder Pain Syndrome/Interstitial Cystitis and Considerations for Designing Future Trials
Soleimani et al. The effectiveness of sublingual misoprostol in prevention of bleeding during cesarean delivery
CN206257213U (zh) 一种钢丝绳加长装置
AU626390B2 (en) Method for silicon reduction with dimercaptosuccinic acid (dmsa)
JPS5256076A (en) Process of adsorption or tion exchange of moving bed type and its equi pment
WO2023042209A3 (en) Treatment of myeloid malignancies
Butler Treatment of Refractory Donor Site Seromas with Percutaneous Instillation of Tisseel Fibrin Sealant
CN204636541U (zh) 一种结核病人痰样处理器
JPS5431098A (en) Regenerating method for activated alumina particles

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application